Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
Utkarsh Goel, Shaji Kumar(Mayo Clinic in Arizona), Francis K. Buadi, Morie A. Gertz(Mayo Clinic in Arizona), Nelson Leung(Memorial Sloan Kettering Cancer Center), Robert A. Kyle(Mayo Clinic in Arizona), Prashant Kapoor, Amie Fonder, Moritz Binder(Mayo Clinic in Arizona), Yi L. Hwa, Rahma Warsame, Charalampos Charalampous(The Ohio State University Wexner Medical Center), S. Vincent Rajkumar(Mayo Clinic), Wilson I. Gonsalves(Mayo Clinic), Taxiarchis Kourelis, Martha Q. Lacy, Yi Lin, Suzanne R. Hayman, Angela Dispenzieri(WinnMed), Miriam Hobbs, David Dingli
Cited by 16
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k